reference/24091750

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24091750

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase I\|Clinical Trial, Phase II\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	7574
issn	1557-3265 1078-0432
issueIdentifier	22
pageRange	7566-7574
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	7566
bibliographicCitation	Raymond E, Kahatt C, Rigolet MH, Sutherland W, Lokiec F, Alexandre J, Tombal B, Elman M, Lee MS, MacDonald JR, Cullen M, Misset JL, Cvitkovic E. Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials. Clin Cancer Res. 2004 Nov 15;10(22):7566–74. doi: 10.1158/1078-0432.ccr-04-0869. PMID: 15569987.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e155cdb0063ff48929ab078b090c36b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea0bdc48c15e7197ae1b2e9de04db773 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0aa998fb4ce4a0cd53dc6fd95e0dd888 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5564458e21f21524bdd6efbd21145ea3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_90a58e198849eb98939eafaf993d7f23 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_88f1dcf01932c51acd860dd8081ad259 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0093-8408 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2ee54a34b669c39fe34e2f5a89b7d7ea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6f74c379288344a3053219b22961befe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0371f0abc0635e1c2c3b0bba39ebfc1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dbe9bcb89b20f6e61624aa5181284af2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbc2f698295bf7ed7a8871fe9bff3b43 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1c7899cb0ddc981fee0b3bc8f9d6872 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_81b499fb13408507abe6025e882014b5
date	2004-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1158/1078-0432.ccr-04-0869 https://pubmed.ncbi.nlm.nih.gov/15569987
isPartOf	https://portal.issn.org/resource/ISSN/1078-0432 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794 https://portal.issn.org/resource/ISSN/1557-3265
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials
discusses	http://id.nlm.nih.gov/mesh/M0028268 http://id.nlm.nih.gov/mesh/M0268775 http://id.nlm.nih.gov/mesh/M0019703
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D014785Q000187 http://id.nlm.nih.gov/mesh/D012717Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D018906Q000627 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D017209 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D011379 http://id.nlm.nih.gov/mesh/D004596 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D013997 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148189 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID638015 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID344200

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135844626

Total number of triples: 56.